CTRI/2019/06/019628尚未招募未知
Epigenetic regulation of placental peroxisome proliferator activatedreceptor (PPAR) in women delivering low birth weight babies
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Singleton pregnancy, delivering at term
- •(total gestation greater than or equal to 37 weeks)
排除标准
- •History of cardiovascular disease, seizure disorder and liver disease, bleeding disorders, HIV or HBsAg positive
研究者
相似试验
进行中（未招募）
不适用
Effects of the activation of PPARs in the orphan hepatic disease primary biliary cirrhosisp to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively examine the therapeutic effects of bezafibrate (a pan-agonist activating PPARalpha/delta/gamma) in patients with early-stage PBC with a specific focus on improvement of liver functions, inflammation, lipid profile, oxidative status and endothelial function.EUCTR2011-004681-15-ATMedizinische Universität Graz
招募中
不适用
Regulation of exosome proteins in type 2 diabetesCTRI/2020/12/029975Indian Council of Medical Research
进行中（未招募）
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis CNL-OMON31787Vrije Universiteit Medisch Centrum50
已完成
不适用
Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome?Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndromeInfections and InfestationsHuman Immunodeficiency VirusISRCTN78808170Academic Medical Centre (AMC) (The Netherlands)15